Allergy Therapeutics is writing a story of resilience ... Its August results hinted at a turning point. In the second half of the financial year, the company posted its first revenue growth ...

2024 has been a turning point in the fight against Alzheimer ... with new generation therapeutics recently succeeding in clinical trials to achieve regulatory approval. For the past 30 years ...

We came across a bullish thesis on AbCellera Biologics Inc. (ABCL) on Twitter by Jack Prescott. In this article, we will ...

TG Therapeutics, Inc. (NASDAQ ... Beyond CF and pain, Vertex has focused its pipeline around genetically driven diseases with the potential for a transformative clinical benefit.

Synthesis Bioventures founder Professor Andrew Wilks is more qualified than most fund managers to know about what makes drug ...

Its pipeline also includes Claudin 18.2-directed ADC BMS-986476 in phase 2 for gastrointestinal and pancreatic cancer, acquired as a result of its acquisition of Turning Point Therapeutics for $4. ...

Welcome to day 1 of the J.P. Morgan Healthcare Conference, the industry's most significant dealmaking event each year.  | For ...

Compared to previously launched biosimilars, these therapeutics are gaining market ... This could be an important turning point for manufacturers, such as Boehringer Ingelheim and Pfizer, that ...

VYNE Therapeutics (VYNE – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Joseph ...

Analyst Mayank Mamtani from B.Riley Financial reiterated a Buy rating on Denali Therapeutics (DNLI – Research Report) and keeping the price ...

Phase 1 interim results expected for SPY002, two distinct extended half-life TL1A antibodies, in 2Q2025 Phase 1 interim results expected for SPY003, an extended half-life IL-23 antibody, in 2H2025 ...